Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
Dual-pathway Inhibition versus Aspirin Monotherapy
Author(s): Dirk Sibbing , Michael J Blaha , Rajinder Chawla , et al Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
Advice for Young Colleagues and Career Pathways
Author(s): Julia Grapsa , Mirvat Alasnag , Barbara Casadei Added: 8 months ago
What is the reasoning behind the porosity of data when it comes to CV outcomes in women?Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Barbara Casadei (British Heart Foundation, University of Oxford, Oxford, UK) who offers her advice… View more
Semaglutide Modulates Key Pathways to Resolve MASH, Proteomic Analysis Reveals
Added: 3 months ago Source:  Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that… View more

Cardiovascular Renal Metabolic
Pulmonary Embolism Management
Author(s): Andrew SP Sharp , Gilles Lemesle , Start date: Oct 07, 2025
Pulmonary Embolism (PE) remains a leading cause of cardiovascular morbidity and mortality, requiring timely intervention and coordinated multidisciplinary care. This session will provide an in-depth analysis of the current PE treatment landscape, including the latest clinical trial updates (HI-PEITHO, PEERLESS), institutional decision-making workflows and collaborative patient management… View more

Intervention

Vascular Disease and Surgery
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Author(s): Wei Gao , Hui Wang , Jian-long Wang , et al Added: 1 week ago

Demographic

Heart Failure
Oxidative Stress Genes Predict Survival in STEMI
Author(s): Shuo-wen Sun , Xing-jie Wang , Ruo-chen Yan , et al Added: 7 months ago

MI/ACS

Prevention & Chronic Conditions
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 1 week ago
Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview Questions:Can you provide an overview… View more

Heart Failure
TCT 25: ENCIRCLE Trial Insights with Dr Daniels & Dr Hamid
Author(s): Nadira Hamid , David V Daniels Added: 2 weeks ago
TCT 2025 – Dr Nadira Hamid (Minneapolis Heart Institute, US), interventional echocardiographer sits down with ENCIRCLE's (Edwards Lifesciences) Principal Investigator, Dr David V Daniels (California Pacific Medical Center, US) to have a deep dive into the latest data with SAPIEN M3.The ENCIRCLE trial (NCT04153292) is a prospective, multicentre, single-arm study evaluating the safety and… View more

Intervention
EuroPCR 25: The DANAMI-3-DEFER Trial
Author(s): Jacob Thomsen Lønborg Added: 5 months ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent… View more

Intervention

MI/ACS